PDS Biotechnology (NASDAQ:PDSB – Get Rating) announced its quarterly earnings data on Wednesday. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.09), MarketWatch Earnings reports. During the same quarter in the previous year, the company earned ($0.14) earnings per share.
NASDAQ PDSB traded up $0.73 on Friday, reaching $4.56. 552,690 shares of the stock traded hands, compared to its average volume of 232,316. PDS Biotechnology has a 12 month low of $3.47 and a 12 month high of $17.85. The firm’s fifty day simple moving average is $5.66 and its 200 day simple moving average is $7.26.
Several analysts recently weighed in on the company. Noble Financial reissued a “buy” rating and issued a $22.00 price objective on shares of PDS Biotechnology in a report on Thursday. Zacks Investment Research cut PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Friday. StockNews.com upgraded PDS Biotechnology to a “sell” rating in a research report on Saturday, April 9th. Finally, Alliance Global Partners dropped their price target on PDS Biotechnology from $18.00 to $16.00 in a research report on Friday. Two analysts have rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $17.00.
PDS Biotechnology Company Profile (Get Rating)
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.
- Get a free copy of the StockNews.com research report on PDS Biotechnology (PDSB)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.